3D Signatures (TSXV:DXD) a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures, is pleased to announce that it has signed a collaboration agreement with l’Institut Universitaire de Cardiologie et de Pneumologie de Québec (“IUCPQ”) to evaluate the clinical application of 3DS’ proprietary TeloView™ software platform alongside DNA sequence analysis in lung cancer.

As quoted in the press release:

“Pathologists have a variety of emerging technologies available that may offer new insights into optimal disease management”, states Dr. Joubert. “This pilot is an exciting opportunity to evaluate how three-dimensional telomere analysis may complement other new tools at our disposal to offer potential benefits to healthcare providers, lung cancer patients, and the healthcare system”.

Click here to read the full press release.